Antisense & RNAi therapeutics are novel biologic drugs that are used for inhibiting protein synthesis or modulating gene expressions. These therapeutics have the potential to treat a wide range of diseases including cancer, cardiovascular diseases, neurological disorders and viral infections. Antisense & RNAi therapeutics work by preventing mRNA translation into disease-causing proteins using different techniques including siRNA and miRNA. The global antisense & RNAi therapeutics market is estimated to be valued at US$ 6.38 Bn in 2024 and is expected to exhibit a CAGR of 18.% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

Increasing adoption by pharmaceutical companies is estimated to drive the growth of the global antisense & RNAi therapeutics market over the forecast period. The increasing R&D investment by major players for the development of novel antisense & RNAi therapeutics is further expected to propel the market growth. For instance, according to Coherent Market Insights’ analysis, the R&D expenditure on RNAi therapeutics by 20 major pharmaceutical companies increased from US$ 700 million in 2015 to more than US$ 1 billion in 2020.

Additionally, growing clinical pipeline is also anticipated to aid in market growth. As of 2022, over 100 antisense & RNAi therapeutics are under clinical investigation worldwide for various disease indications such as cancer, genetic disorders, cardiovascular diseases and infectious diseases.

SWOT Analysis
Strength: The global antisense & RNAi therapeutics market offers several advantages over conventional drug development. Therapeutics using these technologies can selectively target disease-causing genes without affecting others. They also have high specificity to silence only the target gene expression. Antisense & RNAi therapeutics are generated from naturally occurring processes in cells, making them relatively safer than other drug classes.
Weakness: Developing antisense & RNAi therapeutics is technically challenging and expensive. The delivery and stability of nucleic acid therapeutics inside the body also poses challenges as they can be degraded rapidly by enzymes. Their specificity also means a particular molecule may only work against one disease subtype.
Opportunity: The market has opportunities for antisense & RNAi therapeutics in treating cancer, cardiovascular, respiratory, neurological, and infectious diseases. As the understanding of molecular pathways improves, more disease targets can be discovered. Advances in formulation and delivery technologies will improve stability and specificity of such therapeutics.
Threats: Chemical modifications to improve properties may compromise safety profiles over time. Conventional drugs may achieve superior efficacy or have fewer issues with delivery and stability. Biosimilars can capture market share once blockbuster products lose exclusivity. Regulatory guidelines are still evolving for these new modalities.

Key Takeaways
The global antisense & RNAi therapeutics market size is expected to witness high growth.

North America currently dominates due to presence of major players and availability of funding for research. However, Asia Pacific is expected to see fastest growth during the forecast period driven by expansion of biotech industry and biologics manufacturing capabilities in China, India, and South Korea.

Key players

operating in the global antisense & RNAi therapeutics market are Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticals, Inc., Bio-Path Holdings Inc., Percheron Therapeutics Limited, GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc. and Arbutus Biopharma.

 Get more insights on this topic: https://www.newsanalyticspro.com/global-antisense-rnai-therapeutics-market-industry-insightstrendsglobal-antisense-rnai-therapeutics-market/

Explore more information on this topic, Please visit: https://captionssky.com/footwear-sole-materials-an-analysis-of-modern-trends-and-future-outlook/